Laxar, D.; Schaden, E.; Wiegele, M.; Hötzenecker, K.; Schwarz, S.; Gratz, J.
Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. J. Clin. Med. 2023, 12, 3020.
https://doi.org/10.3390/jcm12083020
AMA Style
Laxar D, Schaden E, Wiegele M, Hötzenecker K, Schwarz S, Gratz J.
Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. Journal of Clinical Medicine. 2023; 12(8):3020.
https://doi.org/10.3390/jcm12083020
Chicago/Turabian Style
Laxar, Daniel, Eva Schaden, Marion Wiegele, Konrad Hötzenecker, Stefan Schwarz, and Johannes Gratz.
2023. "Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy" Journal of Clinical Medicine 12, no. 8: 3020.
https://doi.org/10.3390/jcm12083020
APA Style
Laxar, D., Schaden, E., Wiegele, M., Hötzenecker, K., Schwarz, S., & Gratz, J.
(2023). Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy. Journal of Clinical Medicine, 12(8), 3020.
https://doi.org/10.3390/jcm12083020